Johnson & Johnson said on Thursday it planned to file for approvals of more than 30 major products by the end of 2016 as the diversified healthcare company looks to restore growth to a medical device and diagnostics division that has been overshadowed by its drugs business in recent years.The company, prior to a review of the division for analysts and investors, said its recently launched products and extensive pipeline position it for continued growth.J&J also said it would expand business with a significant focus on fast-growing emerging markets, particularly China and Russia."Building on our 28 year history in China, we are capitalizing on our established footprint to grow and expand our overall business," Chief Financial Officer Dominic Caruso said in a statement.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ fell by 0.05% or $-0.05/share to $100.39. In the past year, the shares have traded as low as $82.12 and as high as $101.98. On average, 7985400 shares of JNJ exchange hands on a given day and today's volume is recorded at 680767.
Source
